- Role of asymptomatic hyperuricemia in the progression of chronic kidney disease and cardiovascular disease
-
Waheed Y, Yang F, Sun D
- KMID: 2521724
- Korean J Intern Med.
- 2021 Nov;36(6):1281-1293.
- doi: 10.3904/kjim.2020.340
Previous research has investigated whether hyperuricemia serves as an independent risk factor for cardiovascular and renal diseases. Hyperuricemia is defined as an abnormally high level of uric acid (UA; i.e.,... -
- CITED
-
- Close
- SHARE
-
- Close
- The role of roxadustat in chronic kidney disease patients complicated with anemia
-
Liu J, Yang F, Waheed Y, Li S, Liu K, Zhou X
- KMID: 2539967
- Korean J Intern Med.
- 2023 Mar;38(2):147-156.
- doi: 10.3904/kjim.2022.318
The incidence of chronic kidney disease (CKD) is increasing worldwide and the current prevalence rate is 13.4%. There are > 120 million CKD patients in China and this number is... -
- CITED
-
- Close
- SHARE
-
- Close
- A retrospective study on the efficacy of Roxadustat in peritoneal dialysis patients with erythropoietin hyporesponsiveness
-
Liu J, Li S, Yang F, Li T, Li R, Waheed Y, Meng C, Li S, Liu K, Tong Y, Xu H, Tian C, Zhou X
- KMID: 2554894
- Korean J Intern Med.
- 2024 May;39(3):488-500.
- doi: 10.3904/kjim.2023.520
Background/Aims: Roxadustat, an oral medication for treating renal anemia, is a hypoxia-inducible factor prolyl hydroxylase inhibitor used for regulating iron metabolism and promoting erythropoiesis. To investigate the efficacy and safety... -
- CITED
-
- Close
- SHARE
-
- Close
